Jamerson, Brenda D.

Prevalence of Sexual Dysfunction Among Newer Antidepressants

Clayton, A. H., Pradko, J. F., Croft, H. A., Montano, C. B., Leadbetter, R. A., Bolden-Watson, C., Bass, K. I., Donahue, R. M. J., Jamerson, B. D., & Metz, A. (2002) · The Journal of Clinical Psychiatry

Sexual function and dysfunction studiesTreatment of Major Depression

Cited by 542

Bupropion SR vs. Placebo for Weight Loss in Obese Patients with Depressive Symptoms

Jain, A. K., Kaplan, R. A., Gadde, K. M., Wadden, T. A., Allison, D. B., Brewer, E. R., Leadbetter, R. A., Richard, N., Haight, B., Jamerson, B. D., et al. (2002) · Obesity Research

Pharmacology and Obesity TreatmentEating Disorders and Behaviors

Cited by 205

Bupropion SR as an aid to smoking cessation in smokers treated previously with bupropion: a randomized placebo-controlled study

Gonzales, D. H., Nides, M. A., Ferry, L. H., Kustra, R. P., Jamerson, B. D., Segall, N., Herrero, L. A., Krishen, A., Sweeney, A., Buaron, K., et al. (2001) · Clinical Pharmacology & Therapeutics

Smoking Behavior and CessationSubstance Abuse Treatment and Outcomes

Cited by 143

Effects of a NR2B selective NMDA glutamate antagonist, CP‐101,606, on dyskinesia and parkinsonism

Nutt, J. G., Gunzler, S. A., Kirchhoff, T., Hogarth, P., Weaver, J. L., Krams, M., Jamerson, B., Menniti, F. S., & Landen, J. W. (2008) · Movement Disorders

Parkinson's Disease Mechanisms and TreatmentsDeep Brain Stimulation and Movement Disorders

Cited by 133

Effect of Nonnicotine Pharmacotherapy on Smoking Behavior

Kotlyar, M., Golding, M., Hatsukami, D. K., & Jamerson, B. D. (2001) · Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy

Smoking Behavior and CessationSubstance Abuse Treatment and Outcomes

Cited by 32